Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

• Autores principales: Teodoro Iturbe-Hernandez (Autor), Luis García de Guadiana Romualdo (Autor), Ignacio Gil Ortega (Autor), Antonio Martínez Francés (Autor), Olga Meca Birlanga (Autor), Juan José Cerezo-Manchado (Autor)
• Formato: Libro
• Publicado: BioExcel Publishing Ltd, 2020-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Atrial fibrillation is a frequent complication among patients with severe coronavirus disease-2019 (COVID-19) infection. Both direct and indirect mechanisms through COVID-19 have been described to explain this relationship. COVID-19 infection increases the risk of developing both arterial and venous...